Postherpetic Neuralgia Medication
- Author: W Alvin McElveen, MD; Chief Editor: Robert A Egan, MD more...
The goal of therapy for postherpetic neuralgia (PHN) is to reduce morbidity through the use of tricyclic antidepressants, anticonvulsants, anesthetics, analgesics, corticosteroids, and antiviral agents. A recently approved vaccine is also effective for preventing herpes zoster (HZ) outbreaks and PHN. A recent trial demonstrated that the combination of gabapentin and nortriptyline was more efficacious than either drug as monotherapy for neuropathic pain. Another study found that a single 60-minute treatment with the high-concentration capsaicin patch NGX-4010 reduced PHN for up to 12 weeks regardless of concomitant systemic neuropathic pain medication use.
Complex group of drugs that have central and peripheral anticholinergic effects as well as sedative effects. They have central effects on pain transmission. They block the active reuptake of norepinephrine and serotonin.
By inhibiting reuptake of serotonin and/or norepinephrine by presynaptic neuronal membrane, may increase synaptic concentration in CNS. Useful as analgesic for certain types of chronic and neuropathic pain.
Has demonstrated effectiveness in treatment of chronic pain; by inhibiting reuptake of serotonin and/or norepinephrine by presynaptic neuronal membrane, may increase synaptic concentration in CNS; pharmacodynamic effects such as desensitization of adenyl cyclase and down-regulation of beta-adrenergic receptors and serotonin receptors also appear to play role in its mechanisms of action.
Pain control is essential to quality patient care; it ensures patient comfort and promotes pulmonary toilet. Most analgesics have sedating properties, which are beneficial for patients who experience pain.
Natural chemical derived from plants of Solanaceae family. By depleting and preventing reaccumulation of substance P in peripheral sensory neurons, may render skin and joints insensitive to pain. Substance P thought to be chemomediator of pain transmission from periphery to CNS.
Transient receptor potential vanilloid-1 (TRPV1) agonist indicated for neuropathic pain associated with postherpetic neuralgia. TRPV1 is an ion channel–receptor complex expressed on nociceptive skin nerve fibers. Topical capsaicin causes initial TRPV1 stimulation that may cause pain, followed by pain relief by reduction in TRPV1-expressing nociceptive nerve endings. Neuropathic pain may gradually recur over several months (thought to be caused by TRPV1 nerve fiber reinnervation of treated area).
These agents have anti-inflammatory properties. Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body's immune response to diverse stimuli.
Used to treat various allergic and inflammatory diseases. Decreases inflammation by suppressing migration of polymorphonuclear leukocytes and by reversing increased capillary permeability.
Decreases inflammation by suppressing migration of polymorphonuclear leukocytes and by reversing increased capillary permeability.
Decreases inflammation by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability.
The goal of antivirals is to shorten the clinical course, prevent complications, prevent the development of latency and/or subsequent recurrences, decrease transmission, and eliminate established latency.
Pro-drug that, when biotransformed into active metabolite penciclovir, may inhibit viral DNA synthesis/replication.
These agents stabilize the neuronal membrane so the neuron is less permeable to ions. This prevents the initiation and transmission of nerve impulses, thereby producing the local anesthetic action.
Several recent studies have advocated topical administration of lidocaine as treatment of PHN. Lidocaine gel (5%) in placebo-controlled study showed significant relief in 23 patients studied. Lidocaine tape also decreases severity of pain.
These agents are used to manage severe muscle spasms and provide sedation in neuralgia. They have central effects on pain modulation. Prescribing information for gabapentin products (ie, Neurontin, Gralise, Horizant) describe a statistical improvement in pain scores (ie, a decrease by at least 50% from baseline) compared with placebo when treated for postherpetic neuralgia.
Approved by FDA for use in PHN. Freynhagen et al describe a statistically significant reduction in mean pain score and in pain-related sleep interference compared with placebo. Pregabalin binds with high affinity to alpha2-delta subunit of voltage-gaited calcium channels, thereby reducing excitatory neurotransmitters. Has half-life of approximately 6 h and is eliminated by renal excretion. Decrease in creatinine clearance results in decrease elimination and, therefore, increase in plasma concentration. Peak plasma concentration occurs at one and one half hours after oral intake. Bioavailability is 90%. Following repeated dosing, steady state concentration is achieved at 24-48 h. Can be taken with or without food.
This medication has been approved by the FDA for the treatment of PHN. Has properties common to other anticonvulsants and antineuralgic effects. Exact mechanism of action is not known. Structurally, gabapentin is related to GABA, but it does not interact with GABA receptors. Believed to have a binding site at the alpha 2-delta protein, an auxiliary subunit of voltage-gaited calcium channels. In the rat brain, binding is localized on neuronal dendritic areas. Relevance of these observations to treatment of PHN is not known.
Gabapentin prodrug that provides a longer duration of action compared with gabapentin. Structurally related to neurotransmitter GABA, but has no effect on GABA binding, uptake, or degradation. The mechanism for analgesic activity is unknown. Approved by the FDA for PHN.
Used for prevention of HZ outbreak.
A randomized, double-blind, placebo-controlled trial included 38,560 patients age 60 years and older for 3.1-year median surveillance; 95% completed the trial. HZ development decreased 51.3% (P < 0.001) and PHN decreased 66.5% (P < 0.001). In the ZEST trial, the vaccine significantly reduced the risk by 70% in individuals aged 50-59 years.
Hicks LD, Cook-Norris RH, Mendoza N, Madkan V, Arora A, Tyring SK. Family history as a risk factor for herpes zoster: a case-control study. Arch Dermatol. 2008 May. 144(5):603-8. [Medline].
Helgason S, Petursson G, Gudmundsson S, Sigurdsson JA. Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up. BMJ. 2000 Sep 30. 321(7264):794-6. [Medline].
Delaney A, Colvin LA, Fallon MT, et al. Postherpetic neuralgia: from preclinical models to the clinic. Neurotherapeutics. 2009 Oct. 6(4):630-7. [Medline].
Spiegel R, Miron D, Lumelsky D, Horovitz Y. Severe Meningoencephalitis Due to Late Reactivation of Varicella-Zoster Virus in an Immunocompetent Child. J Child Neurol. 2009 Jun 3. [Medline].
Haanpaa M, Dastidar P, Weinberg A, et al. CSF and MRI findings in patients with acute herpes zoster. Neurology. 1998 Nov. 51(5):1405-11. [Medline].
Dworkin RH, White R, O'Connor AB, Hawkins K. Health care expenditure burden of persisting herpes zoster pain. Pain Med. 2008 Apr. 9(3):348-53. [Medline].
Brisson M. Estimating the number needed to vaccinate to prevent herpes zoster-related disease, health care resource use and mortality. Can J Public Health. 2008 Sep-Oct. 99(5):383-6. [Medline].
Schmader K, Levin M, Gnann J, McNeil S, Vesikari T, et al. Efficacy, immunogenicity, safety, and tolerability of zoster vaccine (ZV) in subjects 50 to 59 years of age (Poster/Abstract). Infectious Diseases Society of America. The 48th Annual Meeting of the Infectious Diseases Society of America. 10-21-2010. Vancouver, British Columbia, Canada:Ref Type: Abstract: 3363.
Chen JY, Chang CY, Feng PH, Chu CC, So EC, Hu ML. Plasma vitamin C is lower in postherpetic neuralgia patients and administration of vitamin C reduces spontaneous pain but not brush-evoked pain. Clin J Pain. 2009 Sep. 25(7):562-9. [Medline].
Kanai A, Okamoto T, Suzuki K, Niki Y, Okamoto H. Lidocaine eye drops attenuate pain associated with ophthalmic postherpetic neuralgia. Anesth Analg. 2010 May 1. 110(5):1457-60. [Medline].
Benzon HT, Chekka K, Darnule A, Chung B, Wille O, Malik K. Evidence-based case report: the prevention and management of postherpetic neuralgia with emphasis on interventional procedures. Reg Anesth Pain Med. 2009 Sep-Oct. 34(5):514-21. [Medline].
Gilron I, Bailey JM, Tu D, Holden RR, Jackson AC, Houlden RL. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet. 2009 Oct 10. 374(9697):1252-61. [Medline].
Irving GA, Backonja M, Rauck R, Webster LR, Tobias JK, Vanhove GF. NGX-4010, a Capsaicin 8% Dermal Patch, Administered Alone or in Combination With Systemic Neuropathic Pain Medications, Reduces Pain in Patients With Postherpetic Neuralgia. Clin J Pain. 2011 Jul 12. [Medline].
Baron R, Saguer M. Mechanical allodynia in postherpetic neuralgia: evidence for central mechanisms depending on nociceptive C-fiber degeneration. Neurology. 1995 Dec. 45(12 Suppl 8):S63-5. [Medline].
Bowsher D. The management of postherpetic neuralgia. Postgrad Med J. 1997 Oct. 73(864):623-9. [Medline].
Choo PW, Galil K, Donahue JG, et al. Risk factors for postherpetic neuralgia. Arch Intern Med. 1997 Jun 9. 157(11):1217-24. [Medline].
Freynhagen R, Strojek K, Griesing T, et al. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain. 2005 Jun. 115(3):254-63. [Medline].
Johnson RW. Herpes zoster and postherpetic neuralgia. Optimal treatment. Drugs Aging. 1997 Feb. 10(2):80-94. [Medline].
Kotani N, Kushikata T, Hashimoto H, et al. Intrathecal methylprednisolone for intractable postherpetic neuralgia. N Engl J Med. 2000 Nov 23. 343(21):1514-9. [Medline].
Merritt HH. A Textbook of Neurology. 1979. 90.
Nurmikko T. Clinical features and pathophysiologic mechanisms of postherpetic neuralgia. Neurology. 1995 Dec. 45(12 Suppl 8):S54-5. [Medline].
Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005 Jun 2. 352(22):2271-84. [Medline].
Rath SA, Braun V, Soliman N, et al. Results of DREZ coagulations for pain related to plexus lesions, spinal cord injuries and postherpetic neuralgia. Acta Neurochir (Wien). 1996. 138(4):364-9. [Medline].
Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA. 1998 Dec 2. 280(21):1837-42. [Medline].
Rowbotham MC, Davies PS, Fields HL. Topical lidocaine gel relieves postherpetic neuralgia. Ann Neurol. 1995 Feb. 37(2):246-53. [Medline].
Tyring S, Barbarash RA, Nahlik JE, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group. Ann Intern Med. 1995 Jul 15. 123(2):89-96. [Medline].
Watson CP. Postherpetic neuralgia. Neurol Clin. 1989 May. 7(2):231-48. [Medline].
Watson CP, Vernich L, Chipman M, Reed K. Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial. Neurology. 1998 Oct. 51(4):1166-71. [Medline].
Watson CPN, Gershon AA. Herpes Zoster and Post Herpetic Neuralgia. Vol 11. 2001:90-93, 108-109.
Whitley RJ, Shukla S, Crooks RJ. The identification of risk factors associated with persistent pain following herpes zoster. J Infect Dis. 1998 Nov. 178 Suppl 1:S71-5. [Medline].